These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 34647694)

  • 1. Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum.
    Tosun D; Demir Z; Veitch DP; Weintraub D; Aisen P; Jack CR; Jagust WJ; Petersen RC; Saykin AJ; Shaw LM; Trojanowski JQ; Weiner MW;
    Alzheimers Dement; 2022 Jul; 18(7):1370-1382. PubMed ID: 34647694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of Alzheimer's disease pathology to biological and clinical progression: A longitudinal study across two cohorts.
    Zhang W; Wang HF; Kuo K; Wang L; Li Y; Yu J; Feng J; Cheng W
    Alzheimers Dement; 2023 Aug; 19(8):3602-3612. PubMed ID: 36840615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measures of cortical microstructure are linked to amyloid pathology in Alzheimer's disease.
    Spotorno N; Strandberg O; Vis G; Stomrud E; Nilsson M; Hansson O
    Brain; 2023 Apr; 146(4):1602-1614. PubMed ID: 36130332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOE effects on regional tau in preclinical Alzheimer's disease.
    Young CB; Johns E; Kennedy G; Belloy ME; Insel PS; Greicius MD; Sperling RA; Johnson KA; Poston KL; Mormino EC; ;
    Mol Neurodegener; 2023 Jan; 18(1):1. PubMed ID: 36597122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease.
    Huang SY; Zhang YR; Guo Y; Du J; Ren P; Wu BS; Feng JF; ; Cheng W; Yu JT
    Alzheimers Dement; 2024 May; 20(5):3251-3269. PubMed ID: 38501315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Pathologic and Volumetric Biomarker Changes With Cognitive Decline in Clinically Normal Adults.
    Hanseeuw BJ; Jacobs HIL; Schultz AP; Buckley RF; Farrell ME; Guehl NJ; Becker JA; Properzi M; Sanchez JS; Quiroz YT; Vannini P; Sepulcre J; Yang HS; Chhatwal JP; Gatchel J; Marshall GA; Amariglio R; Papp K; Rentz DM; Normandin M; Price JC; Healy BC; El Fakhri G; Sperling RA; Johnson KA
    Neurology; 2023 Dec; 101(24):e2533-e2544. PubMed ID: 37968130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid-β but not tau accumulation is strongly associated with longitudinal cognitive decline.
    Wang W; Huang J; Qian S; Zheng Y; Yu X; Jiang T; Ai R; Hou J; Ma E; Cai J; He H; Wang X; Xie C
    CNS Neurosci Ther; 2024 Jul; 30(7):e14860. PubMed ID: 39014268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease.
    Lantero-Rodriguez J; Salvadó G; Snellman A; Montoliu-Gaya L; Brum WS; Benedet AL; Mattsson-Carlgren N; Tideman P; Janelidze S; Palmqvist S; Stomrud E; Ashton NJ; Zetterberg H; Blennow K; Hansson O
    Mol Neurodegener; 2024 Feb; 19(1):19. PubMed ID: 38365825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effects of sleep duration and physical activity on cognitive performance are influenced by β-amyloid and brain volume but not tau burden among cognitively unimpaired older adults.
    Aslanyan V; Ortega N; Fenton L; Harrison TM; Raman R; Mack WJ; Pa J
    Neuroimage Clin; 2023; 39():103460. PubMed ID: 37379733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated Tau PET Signal Depends on Abnormal Amyloid Levels and Correlates with Cognitive Impairment in Elderly Persons without Dementia.
    Zhang RQ; Chen SD; Shen XN; Yang YX; Lu JY; Cui M; Zuo CT; Dong Q; Tan L; Yu JT;
    J Alzheimers Dis; 2020; 78(1):395-404. PubMed ID: 32986669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual cognition in non-amnestic Alzheimer's disease: Relations to tau, amyloid, and cortical atrophy.
    Putcha D; Brickhouse M; Touroutoglou A; Collins JA; Quimby M; Wong B; Eldaief M; Schultz A; El Fakhri G; Johnson K; Dickerson BC; McGinnis SM
    Neuroimage Clin; 2019; 23():101889. PubMed ID: 31200149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.
    Malpetti M; Kievit RA; Passamonti L; Jones PS; Tsvetanov KA; Rittman T; Mak E; Nicastro N; Bevan-Jones WR; Su L; Hong YT; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
    Brain; 2020 May; 143(5):1588-1602. PubMed ID: 32380523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional Tau Deposition Reflects Different Pathways of Subsequent Neurodegeneration and Memory Decline in Cognitively Normal Older Adults.
    Chen X; Toueg TN; Harrison TM; Baker SL; Jagust WJ
    Ann Neurol; 2024 Feb; 95(2):249-259. PubMed ID: 37789559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer's disease.
    Yang HS; Yau WW; Carlyle BC; Trombetta BA; Zhang C; Shirzadi Z; Schultz AP; Pruzin JJ; Fitzpatrick CD; Kirn DR; Rabin JS; Buckley RF; Hohman TJ; Rentz DM; Tanzi RE; Johnson KA; Sperling RA; Arnold SE; Chhatwal JP
    Brain; 2024 Jun; 147(6):2158-2168. PubMed ID: 38315899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.